India Pharma Outlook Team | Monday, 10 November 2025
Lupin has unveiled an ambitious tactical plan aimed at accelerating its growth through a strong product pipeline, widened market reach, and improved financial health. The company's latest update emphasizes a tightly managed approach to both portfolio diversification and innovation-led expansion.
Lupin plans a slew of major product launches; among them is Risperdal Consta, a product that is going to strengthen the company's position in central nervous system therapies, while a generic version of Ravicti - recently launched - will be used to exploit global niche markets.
Locally, the company has set itself a very challenging goal of the release of more than 80 new products, of which the key launches such as Semaglutide-based formulations will be instrumental in the diabetes segment growth.
Also Read: IPC to Set Quality Standards for Key Anti-TB Medicines
Besides this, Lupin is expanding its biosimilars portfolio, aspiring to have five biosimilar products introduced by the market by FY2030, thus confirming its injection into high-value, technology-intensive segments.
On the financial side, the company is expecting the tax rate to be within the range of 21%-22% by FY2026, and is forecasting that its India formulations business will be able to beat the Indian Pharmaceutical Market (IPM) by 1.2 to 1.3 times.
Lupin's strategic plan is centered around a far-sighted focus on innovation, operational efficiency, and customer loyalty. As a result of new product launches and the robust biosimilar pipeline, the company intends to secure steady growth and thereby enhance its standing in the international pharmaceutical arena.
.jpg)
.jpg)
